Scientists have uncovered why two seemingly opposite approaches to targeting the same brain receptor both promote weight loss. In mice, activating the GIP receptor in the brainstem reduced appetite, while blocking it in the hypothalamus removed a kind of «brake» on fullness signals. The researchers used genetically engineered mice — some lacking GIPR in the brainstem, others in the hypothalamus, and a control group with normal receptors — to pinpoint the brain regions responsible. They also found that combining GIPR-targeting treatments with GLP-1 drugs (like those in Wegovy and Ozempic) could produce stronger weight loss effects. This insight could lead to more effective and tailored obesity treatments by understanding how different drug combinations interact with specific brain circuits.
About the Author
